跳到正文
原文
Endpoints News 生物医药· Ryan Cross·· 10 天前AI 评分35

Oyster Therapeutics 获 6000 万美元用于开发Tau蛋白降解药物

London startup raises $60M for degraders aimed at Alzheimer’s protein tau

AI 导读

Oyster Therapeutics 获得 6000 万美元融资,致力于开发针对阿尔茨海默病致病Tau蛋白的口服降解药物。

正文

Oys­ter Ther­a­peu­tics has raised $60 mil­lion to de­vel­op pills that de­stroy path­o­gen­ic forms of tau, a brain pro­tein im­pli­cat­ed in Alzheimer’s dis­ease.
The Se­ries A-2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news